You just read:

SELLAS Life Sciences Group Announces Initiation of Galinpepimut-S (WT1 Cancer Vaccine) Phase 1 Clinical Trial in Combination with PD-1 Checkpoint Inhibitor for Patients with Ovarian Cancer

News provided by

SELLAS Life Sciences Group

02 May, 2016, 08:00 ET